The efficacy of targeted and immune‐based therapies in adults with TP53‐mutated acute lymphoblastic leukaemia

Documenti analoghi

• Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer
  di: Hoda Pourhassan, et al.
  Pubblicazione: (2024)
• Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
  di: Vaibhav Agrawal, et al.
  Pubblicazione: (2025)
• The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission
  di: Jose Tinajero, et al.
  Pubblicazione: (2025)
• Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia
  di: Tamer Othman, et al.
  Pubblicazione: (2024)
• Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high‐grade hepatotoxicity without adversely impacting outcomes
  di: Jose Tinajero, et al.
  Pubblicazione: (2024)